Bristol-Myers Halts Hepatitis C Drug Study on 'Serious' Safety Issue - Wall Street Journal

InPharm

Bristol-Myers Halts Hepatitis C Drug Study on 'Serious' Safety Issue Wall Street Journal By SAABIRA CHAUDHURI · Bristol-Myers Squibb Co. has suspended its study of a drug intended to treat hepatitis C based on the "emergence of a serious safety issue." The move raises questions about the drug's potential and the $2.5 billion price tag ... Bristol-Myers Suspends Hepatitis C Drug Clinical TrialBloomberg Analyst reads last rites after heart failure scuttles Bristol hep C studyFierceBiotech Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex PharmaTheStreet.com Pharmaceutical Business Review all 36 news articles »